Andrew Baum
Stock Analyst at Citigroup
(2.93)
# 1,641
Out of 5,090 analysts
65
Total ratings
76.74%
Success rate
14.4%
Average return
Main Sectors:
Stocks Rated by Andrew Baum
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $48 → $45 | $52.15 | -13.71% | 13 | Nov 17, 2025 | |
| PFE Pfizer | Maintains: Neutral | $25 → $26 | $26.03 | -0.12% | 11 | Aug 6, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $125 → $115 | $99.72 | +15.32% | 13 | Feb 5, 2025 | |
| RPRX Royalty Pharma | Maintains: Buy | $60 → $40 | $39.73 | +0.68% | 2 | Oct 25, 2024 | |
| ABBV AbbVie | Maintains: Buy | $170 → $215 | $226.08 | -4.90% | 10 | Oct 25, 2024 | |
| LLY Eli Lilly and Company | Maintains: Buy | $675 → $895 | $1,010.31 | -11.41% | 11 | Apr 2, 2024 | |
| ALVO Alvotech | Upgrades: Neutral | $5 → $10 | $5.47 | +82.82% | 3 | Oct 20, 2023 | |
| GSK GSK plc | Downgrades: Neutral | n/a | $48.41 | - | 2 | Jul 5, 2017 |
Bristol-Myers Squibb Company
Nov 17, 2025
Maintains: Neutral
Price Target: $48 → $45
Current: $52.15
Upside: -13.71%
Pfizer
Aug 6, 2025
Maintains: Neutral
Price Target: $25 → $26
Current: $26.03
Upside: -0.12%
Merck & Co.
Feb 5, 2025
Maintains: Buy
Price Target: $125 → $115
Current: $99.72
Upside: +15.32%
Royalty Pharma
Oct 25, 2024
Maintains: Buy
Price Target: $60 → $40
Current: $39.73
Upside: +0.68%
AbbVie
Oct 25, 2024
Maintains: Buy
Price Target: $170 → $215
Current: $226.08
Upside: -4.90%
Eli Lilly and Company
Apr 2, 2024
Maintains: Buy
Price Target: $675 → $895
Current: $1,010.31
Upside: -11.41%
Alvotech
Oct 20, 2023
Upgrades: Neutral
Price Target: $5 → $10
Current: $5.47
Upside: +82.82%
GSK plc
Jul 5, 2017
Downgrades: Neutral
Price Target: n/a
Current: $48.41
Upside: -